Carole L Wallis1, Evgenia Aga2, Heather Ribaudo2, Shanmugam Saravanan3, Michael Norton4, Wendy Stevens5, Nagalingeswaran Kumarasamy3, John Bartlett6, David Katzenstein7. 1. Lancet Laboratories, Johannesburg, South Africa. 2. Statistical Data Analysis Center, Harvard School of Public Health, Boston, Massachusetts. 3. YRG Centre for AIDS Research and Education, Chennai, India. 4. Medical Affairs Therapeutic Area, Virology and Nanotechnology, Global Pharmaceutical Research and Development, AbbVie, Chicago, Illinois. 5. University of Witwatersrand, Johannesburg, South Africa. 6. Duke Global Health Institute, Duke University, Durham, North Carolina Kilimanjaro Christian Medical Centre, Moshi, Tanzania. 7. Division of Infectious Diseases, Stanford University, Palo Alto, California.
Abstract
BACKGROUND: The development of drug resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) has been associated with baseline human immunodeficiency virus (HIV)-1 RNA level (VL), CD4 cell counts (CD4), subtype, and treatment failure duration. This study describes drug resistance and levels of susceptibility after first-line virologic failure in individuals from Thailand, South Africa, India, Malawi, Tanzania. METHODS: CD4 and VL were captured at AIDs Clinical Trial Group (ACTG) A5230 study entry, a study of lopinavir/ritonavir (LPV/r) monotherapy after first-line virologic failure on an NNRTI regimen. HIV drug-resistance mutation associations with subtype, site, study entry VL, and CD4 were evaluated using Fisher exact and Kruskall-Wallis tests. RESULTS: Of the 207 individuals who were screened for A5230, sequence data were available for 148 individuals. Subtypes observed: subtype C (n = 97, 66%) AE (n = 27, 18%), A1 (n = 12, 8%), and D (n = 10, 7%). Of the 148 individuals, 93% (n = 138) and 96% (n = 142) had at least 1 reverse transcriptase (RT) mutation associated with NRTI and NNRTI resistance, respectively. The number of NRTI mutations was significantly associated with a higher study screening VL and lower study screening CD4 (P < .001). Differences in drug-resistance patterns in both NRTI and NNRTI were observed by site. CONCLUSIONS: The degree of NNRTI and NRTI resistance after first-line virologic failure was associated with higher VL at study entry. Thirty-two percent of individuals remained fully susceptible to etravirine and rilpivirine, protease inhibitor resistance was rare. Some level of susceptibility to NRTI remained; however, VL monitoring and earlier virologic failure detection may result in lower NRTI resistance.
BACKGROUND: The development of drug resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) has been associated with baseline human immunodeficiency virus (HIV)-1 RNA level (VL), CD4 cell counts (CD4), subtype, and treatment failure duration. This study describes drug resistance and levels of susceptibility after first-line virologic failure in individuals from Thailand, South Africa, India, Malawi, Tanzania. METHODS:CD4 and VL were captured at AIDs Clinical Trial Group (ACTG) A5230 study entry, a study of lopinavir/ritonavir (LPV/r) monotherapy after first-line virologic failure on an NNRTI regimen. HIV drug-resistance mutation associations with subtype, site, study entry VL, and CD4 were evaluated using Fisher exact and Kruskall-Wallis tests. RESULTS: Of the 207 individuals who were screened for A5230, sequence data were available for 148 individuals. Subtypes observed: subtype C (n = 97, 66%) AE (n = 27, 18%), A1 (n = 12, 8%), and D (n = 10, 7%). Of the 148 individuals, 93% (n = 138) and 96% (n = 142) had at least 1 reverse transcriptase (RT) mutation associated with NRTI and NNRTI resistance, respectively. The number of NRTI mutations was significantly associated with a higher study screening VL and lower study screening CD4 (P < .001). Differences in drug-resistance patterns in both NRTI and NNRTI were observed by site. CONCLUSIONS: The degree of NNRTI and NRTI resistance after first-line virologic failure was associated with higher VL at study entry. Thirty-two percent of individuals remained fully susceptible to etravirine and rilpivirine, protease inhibitor resistance was rare. Some level of susceptibility to NRTI remained; however, VL monitoring and earlier virologic failure detection may result in lower NRTI resistance.
Authors: Johan Vingerhoets; Hilde Azijn; Lotke Tambuyzer; Inge Dierynck; Sandra De Meyer; Laurence Rimsky; Steven Nijs; Goedele De Smedt; Marie-Pierre de Béthune; Gaston Picchio Journal: AIDS Res Hum Retroviruses Date: 2010-06 Impact factor: 2.205
Authors: Kim C E Sigaloff; Tina Ramatsebe; Raquel Viana; Tobias F Rinke de Wit; Carole L Wallis; Wendy S Stevens Journal: AIDS Res Hum Retroviruses Date: 2011-08-05 Impact factor: 2.205
Authors: Carole L Wallis; John W Mellors; Willem D F Venter; Ian Sanne; Wendy Stevens Journal: J Acquir Immune Defic Syndr Date: 2010-04-01 Impact factor: 3.731
Authors: Ravindra K Gupta; Andrew Hill; Anthony W Sawyer; Alessandro Cozzi-Lepri; Viktor von Wyl; Sabine Yerly; Viviane Dias Lima; Huldrych F Günthard; Charles Gilks; Deenan Pillay Journal: Lancet Infect Dis Date: 2009-07 Impact factor: 25.071
Authors: Vinie Kouamou; Justen Manasa; David Katzenstein; Alan M McGregor; Chiratidzo E Ndhlovu; Azure T Makadzange Journal: AIDS Date: 2019-09-01 Impact factor: 4.177
Authors: Julia K Rohr; Prudence Ive; Charles Robert Horsburgh; Rebecca Berhanu; Christopher J Hoffmann; Robin Wood; Andrew Boulle; Janet Giddy; Hans Prozesky; Michael Vinikoor; Mwanza Wa Mwanza; Gilles Wandeler; Mary-Ann Davies; Matthew P Fox Journal: J Acquir Immune Defic Syndr Date: 2018-04-01 Impact factor: 3.731
Authors: Suzanne M McCluskey; Yap Boum; Nicholas Musinguzi; Jessica E Haberer; Jeffrey N Martin; Peter W Hunt; Vincent C Marconi; David R Bangsberg; Mark J Siedner Journal: J Acquir Immune Defic Syndr Date: 2017-10-01 Impact factor: 3.731
Authors: Mitch M Matoga; Mina C Hosseinipour; Evgenia Aga; Heather J Ribaudo; Nagalingeswaran Kumarasamy; John Bartlett; Michael D Hughes Journal: Antivir Ther Date: 2016-10-14
Authors: Lillian Seu; Lloyd B Mulenga; Mpanji Siwingwa; Izukanji Sikazwe; Nason Lambwe; M Bradford Guffey; Benjamin H Chi Journal: J Med Virol Date: 2015-03-05 Impact factor: 2.327
Authors: Philip J Palumbo; Jessica M Fogel; Sarah E Hudelson; Ethan A Wilson; Stephen Hart; Laura Hovind; Estelle Piwowar-Manning; Carole Wallis; Maria A Papathanasopoulos; Mariza G Morgado; Shanmugam Saravanan; Srikanth Tripathy; Joseph J Eron; Joel E Gallant; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Jose H Pilotto; Johnstone Kumwenda; Victor Akelo; Sheela V Godbole; Breno R Santos; Beatriz Grinsztejn; Ravindre Panchia; Suwat Chariyalertsak; Joseph Makhema; Sharlaa Badal-Faesen; Ying Q Chen; Myron S Cohen; Susan H Eshleman Journal: J Acquir Immune Defic Syndr Date: 2018-04-15 Impact factor: 3.731
Authors: Mina Hosseinipour; Julie A E Nelson; Clement Trapence; Sarah E Rutstein; Florence Kasende; Virginia Kayoyo; Blessings Kaunda-Khangamwa; Kara Compliment; Christopher Stanley; Fabian Cataldo; Monique van Lettow; Nora E Rosenberg; Hannock Tweya; Salem Gugsa; Veena Sampathkumar; Erik Schouten; Michael Eliya; Frank Chimbwandira; Levison Chiwaula; Atupele Kapito-Tembo; Sam Phiri Journal: J Acquir Immune Defic Syndr Date: 2017-06-01 Impact factor: 3.731
Authors: Nagalingeswaran Kumarasamy; Evgenia Aga; Heather J Ribaudo; Carole L Wallis; David A Katzenstein; Wendy S Stevens; Michael R Norton; Karin L Klingman; Mina C Hosseinipour; John A Crump; Khuanchai Supparatpinyo; Sharlaa Badal-Faesen; John A Bartlett Journal: Clin Infect Dis Date: 2015-02-18 Impact factor: 9.079